Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate -

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile);   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile)   excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 pharmacodynamic properties). indications include: - severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile);   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile)   excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 pharmacodynamic properties). indications include: - severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftazidime pentahydrate 1.16 g equivalent to ceftazidime 1g - powder for injection - 1 g - active: ceftazidime pentahydrate 1.16 g equivalent to ceftazidime 1g excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: - severe infections: for example: · septicaemia, bacteraemia, peritonitis, meningitis. · infections in immunosuppressed patients. · infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftazidime pentahydrate 2.33 g equivalent to ceftazidime 2g - powder for injection - 2 g - active: ceftazidime pentahydrate 2.33 g equivalent to ceftazidime 2g excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: - severe infections: for example: · septicaemia, bacteraemia, peritonitis, meningitis. · infections in immunosuppressed patients. · infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime;   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime   excipient: sodium carbonate - ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: · severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ceftazidime pentahydrate 2.328 g equivalent to ceftazidime 2 g;   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.328 g equivalent to ceftazidime 2 g   excipient: sodium carbonate - ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: · severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns.

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - ceftazidime pentahydrate - pdr for soln for injection - 250 milligram

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - ceftazidime pentahydrate - pdr for soln inj/inf - 2 grams

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - ceftazidime pentahydrate - pdr+solv for soln for inj - 500 milligram